Background: Over the past 5 years, dabigatran, rivaroxaban and apixaban were approved
for stroke prevention. Phase III studies have shown a lower risk of intracranial bleeding with …

Restarting anticoagulants after an intracerebral hemorrhage (ICH) is one of the challenges
that no physician feels happy to face: the available evidence is very weak to support any …

Background: The intracranial hemorrhage (ICH) risk of oral anticoagulants/non-vitamin K
antagonist oral anticoagulants (NOACs) remains largely unknown. Patients who need oral …

Introduction New target-specific anticoagulants such as the direct thrombin inhibitor
dabigatran and the factor Xa inhibitor rivaroxaban are used in an increasing number of …

Objective: Randomized studies have shown a decreased risk of intracranial hemorrhage
(ICH) with use of novel oral anticoagulants (NOACs). We performed a meta-analysis to …

Background: Rate of major bleeding is generally accepted as a good measure of the risks
associated with anticoagulant therapy, but this may not be true if the proportion of major …

Background: Recent years have seen a change in the use of anticoagulants in the general
population due to the availability of direct oral anticoagulants (DOACs) as an alternative to …

Essentials• Risk of intracranial hemorrhage (ICH) may differ between direct oral
anticoagulants (DOACs).• We compared the risk of ICH between DOACs using network meta …

Introduction Patients taking direct oral anticoagulants (DOACs) are increasingly managed in
emergency departments (ED). It is unknown whether the risk of traumatic intracranial …

Objective We performed a systematic review and meta-analysis to compare the risk of
intracranial hemorrhage (ICH) between direct oral anticoagulants (DOACs) and other …